Abstract:Virus-derived double-stranded RNAs (dsRNAs) are sensed in the cytosol by retinoic acid-inducible gene (RIG)-I-like receptors (RLRs). These induce the expression of type I IFN and proinflammatory cytokines through signaling pathways mediated by the mitochondrial antiviral signaling (MAVS) protein. TNF receptor-associated factor (TRAF) family proteins are reported to facilitate the RLR-dependent expression of type I IFN by interacting with MAVS. However, the precise regulatory mechanisms remain unclear. Here, we show the role of FK506-binding protein 51 (FKBP51) in regulating the dsRNA-dependent expression of type I IFN. The binding of FKBP51 to TRAF6 was first identified by "in vitro virus" selection and was subsequently confirmed with a coimmunoprecipitation assay in HEK293T cells. The TRAF-C domain of TRAF6 is required for its interaction, although FKBP51 does not contain the consensus motif for interaction with the TRAF-C domain. Besides TRAF6, we found that FKBP51 also interacts with TRAF3. The depletion of FKBP51 reduced the expression of type I IFN induced by dsRNA transfection or Newcastle disease virus infection in murine fibroblasts. Consistent with this, the FKBP51 depletion attenuated dsRNA-mediated phosphorylations of IRF3 and JNK and nuclear translocation of RelA. Interestingly, dsRNA stimulation promoted the accumulation of FKBP51 in the mitochondria. Moreover, the overexpression of FKBP51 inhibited RLR-dependent transcriptional activation, suggesting a scaffolding function for FKBP51 in the MAVS-mediated signaling pathway. Overall, we have demonstrated that FKBP51 interacts with TRAF proteins and facilitates the expression of type I IFN induced by cytosolic dsRNA. These findings suggest a novel role for FKBP51 in the innate immune response to viral infection.

Ring finger protein 166 potentiates RNA virus-induced interferon-β production via enhancing the ubiquitination of TRAF3 and TRAF6

RNF26 temporally regulates virus-triggered type I interferon induction by two distinct mechanisms.

RNF144A promotes antiviral responses by modulating STING ubiquitination

Forkhead box O1-mediated ubiquitination suppresses RIG-I-mediated antiviral immune responses

Potential Role of Ring Finger Protein 166 (rnf166), A Member of an Ubiquitin Ligase Subfamily, Involved in Regulation of T Cell Activation

E3 ubiquitin ligase RNF114 promotes vesicular stomatitis virus replication via inhibiting type I interferon production

Ring Finger Protein 215 Negatively Regulates Type I IFN Production via Blocking NF-KB p65 Activation

Ring Finger Protein 215 Negatively Regulates Type I IFN Production via Blocking NF-κB p65 Activation.

Mitochondria-nucleus shuttling FK506-binding protein 51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of type I IFN

RNA‐binding protein RBM47 stabilizes IFNAR1 mRNA to potentiate host antiviral activity

IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infection

RNF123 has an E3 ligase-independent function in RIG-I-like receptor-mediated antiviral signaling

IFI16 Positively Regulates RIG-I-Mediated Type I Interferon Production in a STING-Independent Manner

ZNF205 positively regulates RLR antiviral signaling by targeting RIG-I

E3 ubiquitin ligase RNF6 promotes antiviral immune responses through enhancing the expression of interferon stimulated genes in myeloid cells

Krab-Zinc Finger Protein Znf268a Deficiency Attenuates The Virus-Induced Pro-Inflammatory Response By Preventing Ikk Complex Assembly

SRP54 Negatively Regulates IFN-Beta Production and Antiviral Response by Targeting RIG-I and MDA5

DEAD-box RNA helicase 18 disrupts IRF3-binding to the interferon-β promoter

E3 Ubiquitin Ligase RNF114 Inhibits Innate Immune Response to Red-Spotted Grouper Nervous Necrosis Virus Infection in Sea Perch by Targeting MAVS and TRAF3 to Mediate Their Degradation.

Interferon-Inducible LINC02605 Promotes Antiviral Innate Responses by Strengthening IRF3 Nuclear Translocation

FBXO11 amplifies type I interferon signaling to exert antiviral effects by facilitating the assemble of TRAF3‐TBK1‐IRF3 complex